Abstracts Archive - Page 1926 of 2425 - ACR Meeting Abstracts

Abstract Number: 1904 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor Isotype Testing to Identify Individuals in the Preclinical Period of Rheumatoid Arthritis
M. Kristen Demoruelle¹, Anthony Kahr¹, Mark C. Parish¹, Marie L. Feser¹, Ryan W. Gan², Jason R. Kolfenbach¹, William R. Gilliland³, Jess D. Edison³, Michael H. Weisman⁴, James R. O'Dell⁵, Ted R. Mikuls⁶, Richard M. Keating⁷, Peter K. Gregersen⁸, Jane H. Buckner⁹, Jill M. Norris², V. Michael Holers¹⁰ and Kevin D. Deane¹, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Walter Reed National Military Medical Center, Bethesda, MD, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, Scripps Clinic, La Jolla, CA, ⁸Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA)-related autoantibody (Ab) testing for Abs to cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) are used in the clinical diagnosis of…
Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting
Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
Abstract Number: 1902 • 2014 ACR/ARHP Annual Meeting
Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity
Michelle Ormseth¹, Cecilia P. Chung², Joseph F. Solus³, Annette M. Oeser³, Margery A. Connelly⁴, Jim Otvos⁴ and C Michael Stein³, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Medicine, Vanderbilt University, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴LipoScience, Inc., Raleigh, NC
Background/Purpose GlycA is a novel inflammatory biomarker measured from the nuclear magnetic resonance (NMR) spectra obtained for lipoprotein particle analysis. It represents a distinct peak…
Abstract Number: 1901 • 2014 ACR/ARHP Annual Meeting
Interferon-γ (IFNγ) in Macrophage Activation Syndrome (MAS) Associated with Systemic Juvenile Idiopathic Arthritis (sJIA). High Levels in Patients and a Role in a Murine MAS Model
Claudia Bracaglia¹, Ivan Caiello¹, Kathy De Graaf², Giovanni D'Ario², Florence Guilhot², Walter Ferlin², Lidia Meli¹, Giusi Prencipe¹, Sergio Davì³, Grant Schulert⁴, Angelo Ravelli⁵, Alexei Grom⁶, Cristina De Min² and Fabrizio De Benedetti Sr.¹, ¹Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland, ³Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ⁴Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Istituto Giannina Gaslini and University of Genova, Genova, Italy, ⁶Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: IFNγ is the pivotal mediator in murine models of primary HLH. Given the similarities between primary and secondary (sHLH), including MAS, we analyzed IFNγ…
Abstract Number: 1900 • 2014 ACR/ARHP Annual Meeting
HLA-DRB1*1101, Regulatory Variants of the MHC, and a Regulatory Region Near an Intergenic Long Noncoding RNA on Chromosome 1 Are Risk Factors for Systemic Juvenile Idiopathic Arthritis
Michael J. Ombrello¹, Elaine F. Remmers², Ioanna Tachmazidou³, Alexei Grom⁴, Dirk Föll⁵, Alberto Martini⁶, Marco Gattorno⁷, Seza Ozen⁸, Sampath Prahalad^9,10, Andrew S. Zeft¹¹, John F. Bohnsack¹², Norman T. Ilowite¹³, Jane L. Park¹⁴, Elizabeth D. Mellins¹⁵, Ricardo A. G. Russo¹⁶, Claudio A. Len¹⁷, Sheila K. Feitosa de Oliveira¹⁸, Rae SM Yeung¹⁹, Lucy R. Wedderburn^20,21, Jordi Anton²², Tobias Schwarz²³, Buhm Han²⁴, Richard H. Duerr²⁵, Jean-Paul Achkar²⁶, M. Ilyas Kamboh²⁷, Kenneth M. Kaufman²⁸, Leah C. Kottyan²⁸, Dalila Pinto²⁹, Stephen Scherer³⁰, Marta E. Alarcón-Riquelme³¹, Elisa Docampo Martinez³², Xavier Estivill³³, Ahmet Gul³⁴, Colleen Satorius³⁵, Paul I.W. de Bakker^36,37,38, Soumya Raychaudhuri^37,39,40, Carl D. Langefeld⁴¹, Susan D. Thompson⁴², Eleftheria Zeggini³, Wendy Thomson⁴³, Daniel L. Kastner⁴⁴, Patricia Woo⁴⁵ and International Childhood Arthritis Genetics (INCHARGE) Consortium, ¹Translational Genetics and Genomics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, ⁴Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, ⁶University of Genova, Genova, Italy, ⁷Pediatric Rheumatology, Instituto Giannina Gaslini, Genoa, Italy, ⁸Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, ⁹Emory University School of Medicine, Atlanta, GA, ¹⁰Children's Healthcare of Atlanta, Atlanta, GA, ¹¹Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹²Pediatriacs, University of Utah, Salt Lake City, UT, ¹³Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ¹⁴Pediatric Rheumatology, Stanford University Medical Center, Stanford, CA, ¹⁵Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, ¹⁶Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ¹⁷Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil, ¹⁸Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²⁰University College London (UCL) Institute of Child Health, London, United Kingdom, ²¹Great Ormond Street Hospital, London, United Kingdom, ²²Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ²³Pediatric rheumathology and osteology, University of Wuerzburg, Wuerzburg, Germany, ²⁴Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, ²⁵Department of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, PA, ²⁶Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, ²⁷Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, ²⁸Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁹Genetics and Genomi Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, ³⁰The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, Canada, ³¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³²Unit of Animal Genomics, GIGA-Université de Liège, LIege, Belgium, ³³Genetic Causes of Disease Laboratory, Center for Genomic Regulation, Barcelona, Spain, ³⁴Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁵National Human Genome Research Institute, Bethesda, MD, ³⁶Brighan and Women's Hospital, Harvard Medical School, Boston, MA, ³⁷Broad Institute of MIT and Harvard, Cambridge, MA, ³⁸University Medical Center Utrecht, Utrecht, Netherlands, ³⁹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁴⁰Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴¹Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴²Division and Center for Autoimmune Disease Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴³Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁴⁴Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁴⁵Paediatric Rheumatology Unit, University College London, London, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory disease of unknown etiology. We utilized a genomic approach to interrogate the molecular pathogenesis of…
Abstract Number: 1899 • 2014 ACR/ARHP Annual Meeting
Blockade of Interleukin-33 Signaling Prevents Death in a Mouse Model of Familial Hemophagocytic Lymphohistiocytosis
Julia Rood¹, Portia Kreiger², Erietta Stelekati¹, E. John Wherry¹ and Edward M. Behrens³, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Pathology, Alfred I. duPont Hospital for Children, Wilmington, DE, ³Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose Cytokine storm syndromes, such as macrophage activation syndrome and familial hemophagocytic lymphohistiocytosis (FHL), represent important causes of mortality in pediatric rheumatology. Studies of a…
Abstract Number: 1898 • 2014 ACR/ARHP Annual Meeting
Identification of “autoinflammatory interferonopathies”? a New Class of Autoinflammatory Conditions?
Adriana Almeida de Jesus¹, Zuoming Deng², Stephen Brooks³, Yin Liu⁴, Hanna Kim⁴, Gina A. Montealegre Sanchez⁴, Dawn C. Chapelle⁴, Yan Huang⁴, Philip Hashkes⁵, Gulnara Nasrullayeva⁶, Maria Teresa Terreri⁷, Bita Arabshahi⁸, Marilynn G. Punaro⁹, Lakshmi N. Moorthy¹⁰, Adam Reinhardt¹¹, Clovis A. Silva¹², Emilia I. Sato¹³, Vibke Lilleby¹⁴, Thomas Fleisher¹⁵ and Raphaela Goldbach-Mansky⁴, ¹Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ²Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³NIAMS/NIH, Bethesda, MD, ⁴Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ⁵Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ⁶Head Immunology Department, Azerbaijan Medical University, Baku, Azerbaijan, ⁷University of Federal De Sao Paulo, Sao Paulo, Brazil, ⁸Pediatric Rheumatology, Inova Fairfax Hospital for Children, Fairfax, VA, ⁹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ¹⁰Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ, ¹¹Pediatric Rheumatology, Children's Specialty Physicians, Omaha, NE, ¹²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ¹³Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ¹⁴Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹⁵Chief Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD
Background/Purpose The role of IL-1 in the pathogenesis of many of the monogenic autoinflammatory diseases is clinically validated by the response to IL-1 blocking therapies.…
Abstract Number: 1897 • 2014 ACR/ARHP Annual Meeting
Circulating T-Helper Cell- Associated Cytokines and Chemokines in Localized Scleroderma
Kathryn S. Torok¹, Katherine Kurzinski², Christina Kelsey³, Kelsey Magee⁴, Jonathan Yabes⁵, Abbe N. Vallejo⁶, Thomas A. Medsger Jr.⁷ and Carol A. Feghali-Bostwick⁸, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA, ⁴Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Department of Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissues which results in disfigurement and orthopedic complications, especially when the onset…
Abstract Number: 1880 • 2014 ACR/ARHP Annual Meeting
Moderate Alcohol Consumption Is Associated with Lower Risk (and severity) of Chronic Widespread Pain: Results from a Population-Based Study
Gary J. Macfarlane and Marcus Beasley, Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom
Background/Purpose: Amongst patients with fibromyalgia, alcohol consumption has been reported in a single clinical study to be associated with lower severity of symptoms. This study…
Abstract Number: 1879 • 2014 ACR/ARHP Annual Meeting
The Efficacy of Pregabalin for Treating Fibromyalgia Patients with Moderate or Severe Baseline Widespread Pain
Andrew Clair and Birol Emir, Pfizer Inc, New York, NY
Background/Purpose: Pregabalin has demonstrated efficacy for the treatment of fibromyalgia (FM), but insufficient evidence exists on how the efficacy of pregabalin may differ by baseline…
Abstract Number: 1878 • 2014 ACR/ARHP Annual Meeting
A Combination of Celecoxib and Famciclovir Is Efficacious in the Treatment of Fibromyalgia: Results of a Phase IIa Randomized, Double-Blind, Placebo-Controlled Study
William Pridgen¹, Carol Duffy², Judith Gendreau³ and R Michael Gendreau³, ¹Innovative Med Concepts, Tuscaloosa, AL, ²Biological Sciences, University of Alabama, Tuscaloosa, AL, ³Gendreau Consulting, LLC, Poway, CA
Background/Purpose: Fibromyalgia (FM) is a common chronic pain syndrome with symptoms that include widespread pain, fatigue, sleep disruption and cognitive impairment. It is known that…
Abstract Number: 1877 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes in SLE: Before and after
Elizabeth V. Arkema¹, Kristin Palmsten², Christopher Sjöwall³, Elisabet Svenungsson⁴, Jane E. Salmon⁵ and Julia F Simard⁶, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Pediatrics, University of California, San Diego, La Jolla, CA, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA
Background/Purpose: Numerous investigators have demonstrated that the risks of pre-eclampsia, preterm delivery, and fetal death are increased in lupus pregnancies. Adverse events during pregnancy, delivery,…
Abstract Number: 1876 • 2014 ACR/ARHP Annual Meeting
Influence of Alcohol Consumption on the Risk of SLE Among Women in the Nurses’ Health Studies
Medha Barbhaiya, Bing Lu, Shun-Chiao Chang, Jeffrey A. Sparks, Elizabeth W. Karlson and Karen H. Costenbader, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Prior case-control studies have reported an inverse association between moderate alcohol consumption and the development of SLE. However, case-control studies may be prone to…
Abstract Number: 1875 • 2014 ACR/ARHP Annual Meeting
Can Allopurinol Survival Impact Reverse Depending on Patients’ Characteristics? a Propensity-Score-Based Subgroup Analysis
Na Lu¹, Hyon K. Choi², Maureen Dubreuil^3,4, Qiong Louie-Gao⁵ and Yuqing Zhang¹, ¹Boston University School of Medicine, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Boston University Medical Center, Boston, MA, ⁴Rheumatology, Boston VA HealthCare System, Boston, MA, ⁵Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Several studies have reported that allopurinol use is associated with a decreased risk of death or cardiovascular outcomes. While these studies reported the overall…
Abstract Number: 1874 • 2014 ACR/ARHP Annual Meeting
Obesity Paradox in Recurrent Gout – a Metrological Clarification and Remedy
Uyen Sa D.T. Nguyen^1,2, Qiong Louie-Gao³, Yuqing Zhang⁴, David T. Felson³, Michael P. Lavalley⁵ and Hyon K. Choi⁶, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²Clinical Epidemiology Research &Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Biostatistics, Boston University, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Obesity is a strong risk factor of incident gout, but previous research showed no such association with recurrent gout among gout patients. These paradoxical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].